Sector Chart ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-15 EDT			After hours 18:46:26
11.14 ^USD	+5.59%		11.34	+1.84%

07-14	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
07-14	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
ORIC PHARMACEUTICALS, INC.	1.15B	-	-	-	-	-
WUXI APPTEC CO., LTD.	57.82B
ARGENX SE	53.71B
INSMED INCORPORATED	23.8B					-
BIONTECH SE	23.26B					-
WUXI BIOLOGICS (CAYMAN) INC.	20.7B